Literature DB >> 12649576

11beta-hydroxysteroid dehydrogenase type 1 deficiency ('apparent cortisone reductase deficiency') in a 6-year-old boy.

Ewa M Małunowicz1, Tomasz E Romer, Maria Urban, Artur Bossowski.   

Abstract

OBJECTIVE: We present the 1st case of prepubertal hyperandrogenism because of a defect in the conversion of cortisone (E) to cortisol (F) by hepatic 11beta-hydroxysteroid dehydrogenase type 1. METHODS AND
RESULTS: Clinical and anthropometric data were obtained. Serum androgens and gonadotropins with luteinizing hormone releasing hormone stimulation test, dexamethasone suppression test, and corticotropin-releasing hormone stimulation test were evaluated. Adrenal imaging and urinary steroid profiling by gas chromatography/mass spectrometry were employed. A 6.9-year-old boy presented with precocious pubarche, height (+2.6 SD), accelerated bone age (11.5 years), and Tanner stage 2 pubic hair and genitalia. Serum androgen levels were elevated and dexamethasone suppressible. Serum F was normal, but the E concentration was increased. Central precocious puberty and congenital adrenal hyperplasia were excluded. The excretion of androgen metabolites was moderately increased, but a highly increased tetrahydrocortisone (THE) and a diminished tetrahydrocortisol (THF + allo-THF) excretion was found with a [THF + allo-THF/ THE] ratio of 0.032 (normal controls 1.05 +/- 0.17). The corticotropin-releasing hormone stimulation test showed an exaggerated adrenocorticotropic hormone response, suggesting a relative deficiency of F. Two months of hydrocortisone treatment (17.5 mg daily) failed to suppress androgens adequately. Treatment with dexamethasone (0.375 mg/daily) resulted in androgen suppression.
CONCLUSIONS: In the case of precocious pubarche and accelerated growth, the diagnosis of 11beta-hydroxysteroid dehydrogenase type 1 deficiency ('apparent cortisone reductase deficiency') should be considered. The diagnosis is based on determinations of urinary steroid metabolites. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12649576     DOI: 10.1159/000069326

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  8 in total

Review 1.  Defects of steroidogenesis.

Authors:  A Biason-Lauber; M Boscaro; F Mantero; G Balercia
Journal:  J Endocrinol Invest       Date:  2010-02-24       Impact factor: 4.256

2.  Mutations of the hexose-6-phosphate dehydrogenase gene rarely cause hyperandrogenemic polycystic ovary syndrome.

Authors:  Kenan Qin; Robert L Rosenfield
Journal:  Steroids       Date:  2010-11-02       Impact factor: 2.668

Review 3.  Steroid biomarkers in human adrenal disease.

Authors:  Juilee Rege; Adina F Turcu; Tobias Else; Richard J Auchus; William E Rainey
Journal:  J Steroid Biochem Mol Biol       Date:  2019-01-29       Impact factor: 4.292

Review 4.  11-Oxygenated androgens in health and disease.

Authors:  Adina F Turcu; Juilee Rege; Richard J Auchus; William E Rainey
Journal:  Nat Rev Endocrinol       Date:  2020-03-16       Impact factor: 43.330

5.  The role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome.

Authors:  Minghan Wang
Journal:  Nutr Metab (Lond)       Date:  2005-02-02       Impact factor: 4.169

6.  Poor response to substitution therapy with cortisone acetate in patients with congenital adrenal hyperplasia.

Authors:  Hiroshi Inada; Takuji Imamura; Ryoichi Nakajima; Tsunekazu Yamano
Journal:  Clin Pediatr Endocrinol       Date:  2004-07-07

7.  Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency.

Authors:  Gareth G Lavery; Elizabeth A Walker; Ana Tiganescu; Jon P Ride; Cedric H L Shackleton; Jeremy W Tomlinson; John M C Connell; David W Ray; Anna Biason-Lauber; Ewa M Malunowicz; Wiebke Arlt; Paul M Stewart
Journal:  J Clin Endocrinol Metab       Date:  2008-07-15       Impact factor: 5.958

8.  Novel H6PDH mutations in two girls with premature adrenarche: 'apparent' and 'true' CRD can be differentiated by urinary steroid profiling.

Authors:  G G Lavery; J Idkowiak; M Sherlock; I Bujalska; J P Ride; K Saqib; M F Hartmann; B Hughes; S A Wudy; J De Schepper; W Arlt; N Krone; C H Shackleton; E A Walker; P M Stewart
Journal:  Eur J Endocrinol       Date:  2013-02-01       Impact factor: 6.664

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.